Cytoreductive Surgery Plus Hyperthermic Perioperative Chemotherapy for Selected Patients with Peritoneal Metastases from Colorectal Cancer : A New Standard of Care or an Experimental Approach?

Abstract EN

Peritoneal metastases (PM) are a common presentation for patients with metastatic colorectal cancer (CRC), and the median survival of patients with PM is approximately one year.

In a majority of patients, the disease remains limited to the peritoneal cavity.

Therefore, investigators have applied cytoreductive surgery (CRS) and heated perioperative chemotherapy (HIPEC) as a standard approach for selected patients with PM from CRC.

These investigators have demonstrated a very promising long-term survival in a subset of patients with a limited amount of isolated peritoneal metastatic disease.

This paper presents the data that supports CRS and HIPEC as a treatment option for CRC patients with PM.

These results of treatment are compared and contrasted to the results that can be expected with systemic chemotherapy alone.